Thomas Shrader
Stock Analyst at BTIG
(1.02)
# 3,502
Out of 4,829 analysts
47
Total ratings
25%
Success rate
-2.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Shrader
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALDX Aldeyra Therapeutics | Maintains: Buy | $11 → $9 | $2.20 | +310.02% | 1 | Apr 7, 2025 | |
| OVID Ovid Therapeutics | Maintains: Buy | $5 → $4 | $0.30 | +1,224.50% | 3 | Mar 24, 2025 | |
| PCVX Vaxcyte | Reiterates: Buy | $160 | $31.59 | +406.49% | 4 | Feb 24, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Initiates: Buy | $41 | $11.59 | +253.75% | 1 | Jan 28, 2025 | |
| ALEC Alector | Maintains: Buy | $16 → $5 | $1.20 | +316.67% | 2 | Nov 26, 2024 | |
| ATHA Athira Pharma | Downgrades: Neutral | n/a | $0.27 | - | 3 | Sep 4, 2024 | |
| ACIU AC Immune | Initiates: Buy | $8 | $1.63 | +390.80% | 1 | May 31, 2024 | |
| PMN ProMIS Neurosciences | Initiates: Buy | $8 | $0.50 | +1,496.81% | 1 | Oct 3, 2023 | |
| DTIL Precision BioSciences | Maintains: Buy | $180 → $60 | $5.22 | +1,049.43% | 1 | Jul 28, 2023 | |
| BHVN Biohaven | Reiterates: Buy | $24 | $20.56 | +16.73% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $7 | $1.77 | +295.48% | 2 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $6.14 | +144.30% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $13 | $0.43 | +2,907.87% | 3 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $31 | $67.53 | -54.09% | 3 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $10 | $1.92 | +420.83% | 2 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $22 | $1.05 | +1,995.24% | 2 | Oct 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $14 | $7.64 | +83.25% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $1.47 | +3,369.39% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $2.15 | +644.19% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.35 | - | 1 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $14.79 | - | 2 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $58 | $8.11 | +615.17% | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.28 | +134.38% | 3 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $397 → $346 | $124.40 | +178.14% | 3 | Feb 21, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.91 | - | 1 | Jun 30, 2017 |
Aldeyra Therapeutics
Apr 7, 2025
Maintains: Buy
Price Target: $11 → $9
Current: $2.20
Upside: +310.02%
Ovid Therapeutics
Mar 24, 2025
Maintains: Buy
Price Target: $5 → $4
Current: $0.30
Upside: +1,224.50%
Vaxcyte
Feb 24, 2025
Reiterates: Buy
Price Target: $160
Current: $31.59
Upside: +406.49%
Arcturus Therapeutics Holdings
Jan 28, 2025
Initiates: Buy
Price Target: $41
Current: $11.59
Upside: +253.75%
Alector
Nov 26, 2024
Maintains: Buy
Price Target: $16 → $5
Current: $1.20
Upside: +316.67%
Athira Pharma
Sep 4, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.27
Upside: -
AC Immune
May 31, 2024
Initiates: Buy
Price Target: $8
Current: $1.63
Upside: +390.80%
ProMIS Neurosciences
Oct 3, 2023
Initiates: Buy
Price Target: $8
Current: $0.50
Upside: +1,496.81%
Precision BioSciences
Jul 28, 2023
Maintains: Buy
Price Target: $180 → $60
Current: $5.22
Upside: +1,049.43%
Biohaven
Jun 6, 2023
Reiterates: Buy
Price Target: $24
Current: $20.56
Upside: +16.73%
May 25, 2023
Maintains: Buy
Price Target: $15 → $7
Current: $1.77
Upside: +295.48%
May 18, 2023
Initiates: Buy
Price Target: $15
Current: $6.14
Upside: +144.30%
Mar 28, 2023
Maintains: Buy
Price Target: $68 → $13
Current: $0.43
Upside: +2,907.87%
Mar 20, 2023
Maintains: Buy
Price Target: $26 → $31
Current: $67.53
Upside: -54.09%
Nov 14, 2022
Maintains: Buy
Price Target: $30 → $10
Current: $1.92
Upside: +420.83%
Oct 5, 2022
Maintains: Buy
Price Target: $15 → $22
Current: $1.05
Upside: +1,995.24%
May 24, 2022
Maintains: Buy
Price Target: $31 → $14
Current: $7.64
Upside: +83.25%
Apr 20, 2021
Initiates: Buy
Price Target: $51
Current: $1.47
Upside: +3,369.39%
Mar 8, 2021
Initiates: Buy
Price Target: $16
Current: $2.15
Upside: +644.19%
Feb 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.35
Upside: -
Oct 16, 2020
Downgrades: Neutral
Price Target: n/a
Current: $14.79
Upside: -
Sep 15, 2020
Maintains: Buy
Price Target: $51 → $58
Current: $8.11
Upside: +615.17%
Apr 3, 2020
Maintains: Buy
Price Target: $4 → $3
Current: $1.28
Upside: +134.38%
Feb 21, 2019
Downgrades: Hold
Price Target: $397 → $346
Current: $124.40
Upside: +178.14%
Jun 30, 2017
Downgrades: Hold
Price Target: n/a
Current: $0.91
Upside: -